drugset

drugset / Trial / NCT00505258

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

NCT00505258 ↗

Phase 2 Withdrawn Basilea Pharmaceutica

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.

Timeline

Start: —
Primary completion: —
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ceftobiprole	Small molecule	500 mg	—

Indications